[S] Innovative Approach to Producing Palladium-103 for Auger-Emitting Radionuclide Therapy: A Proof-of-Concept Study

A tétel rövid nézete
dc.contributor.authorLaouameria, Aicha Nour
dc.contributor.authorHunyadi, Mátyás
dc.contributor.authorCsík, Attila
dc.contributor.authorSzűcs, Zoltán
dc.contributor.authorLaouameria, Aicha Nour (2024-) (xxx)
dc.contributor.submitterdepKémiai Tudományok Doktori Iskola -- 10059
dc.contributor.submitterdepTermészettudományi Doktori Tanács
dc.contributor.submitterdepDebreceni Egyetem
dc.date.accessioned2024-03-21T15:09:26Z
dc.date.available2024-03-21T15:09:26Z
dc.date.oa2024-04-02
dc.date.updated2024-03-21T15:09:26Z
dc.description.abstractAuger-emitting radionuclides, exemplified by Pd-103, exhibit considerable therapeutic potential in cancer treatment due to their high cytotoxicity and localized biological impact. Despite these advantages, the separation of such radionuclides presents a complicated challenge, requiring intricate and time-intensive “wet chemistry” methods attributed to the exceptional chemical inertness of the associated metals. This study proposes an innovative solution to this separation challenge through the design and implementation of a piece of radionuclide separation equipment (RSE). The equipment employs a dry distillation approach, capitalizing on differences in partial vapor pressures between irradiated and resulting radioactive metals, with a diffusion-driven extraction method applied to separate Pd-103 radionuclides generated via the proton irradiation of Rh-103 at cyclotron. Our optimization endeavors focused on determining the optimal temperature for effective metal separation and adjusting the diffusion, evaporation, and deposition rates, as well as addressing chemical impurities. The calculations indicate 17% ± 2% separation efficiency with our RSE. Approximately 77 ± 2% and 49 ± 2% of the deposited Pd-103 were isolated on substrates of Nb foil and ZnO-covered W disc, respectively. The proposed innovative dry distillation method that has been experimentally tested offers a promising alternative to conventional separation techniques, enabling enhanced purity and cost-efficient cancer treatment strategies. © 2024 by the authors.
dc.description.correctorTK
dc.identifier.citationPharmaceuticals. -17 : 2 (2024), p. 253, p. 1-13. -Pharmaceuticals (Basel). -1424-8247
dc.identifier.doi10.3390/ph17020253
dc.identifier.issn1424-8247
dc.identifier.opachttps://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM119664
dc.identifier.urihttps://hdl.handle.net/2437/367735
dc.identifier.urlhttps://www.mdpi.com/1424-8247/17/2/253
dc.languageeng
dc.rights.accessopen access journal
dc.rights.ownerMDPI
dc.subject.otheridegen nyelvű folyóiratközlemény külföldi lapban
dc.subject.otherAuger electron therapy
dc.subject.otherdiffusion
dc.subject.otherpalladium-103
dc.subject.otherpartial pressure
dc.subject.otherradioisotope separation
dc.title[S] Innovative Approach to Producing Palladium-103 for Auger-Emitting Radionuclide Therapy: A Proof-of-Concept Study
Fájlok
Eredeti köteg (ORIGINAL bundle)
Megjelenítve 1 - 1 (Összesen 1)
Nem elérhető
Név:
FILE_UP_0_pharmaceuticals-17-00253-v2.pdf
Méret:
6.32 MB
Formátum:
Adobe Portable Document Format
Leírás:
Kiadói változat
Letöltés
Gyűjtemények
Publikációs Adatbázis